JP2005505506A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505506A5
JP2005505506A5 JP2003503220A JP2003503220A JP2005505506A5 JP 2005505506 A5 JP2005505506 A5 JP 2005505506A5 JP 2003503220 A JP2003503220 A JP 2003503220A JP 2003503220 A JP2003503220 A JP 2003503220A JP 2005505506 A5 JP2005505506 A5 JP 2005505506A5
Authority
JP
Japan
Prior art keywords
alkyl
ethyl
hydroxy
oxa
diaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003503220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/018719 external-priority patent/WO2002100399A1/en
Publication of JP2005505506A publication Critical patent/JP2005505506A/ja
Publication of JP2005505506A5 publication Critical patent/JP2005505506A5/ja
Pending legal-status Critical Current

Links

JP2003503220A 2001-06-12 2002-06-12 アルツハイマー病の治療に有用な大環状分子 Pending JP2005505506A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29750501P 2001-06-12 2001-06-12
US33308201P 2001-11-19 2001-11-19
PCT/US2002/018719 WO2002100399A1 (en) 2001-06-12 2002-06-12 Macrocycles useful in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2005505506A JP2005505506A (ja) 2005-02-24
JP2005505506A5 true JP2005505506A5 (enExample) 2006-01-05

Family

ID=26970188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003503220A Pending JP2005505506A (ja) 2001-06-12 2002-06-12 アルツハイマー病の治療に有用な大環状分子

Country Status (6)

Country Link
US (2) US7067507B2 (enExample)
EP (1) EP1395257A1 (enExample)
JP (1) JP2005505506A (enExample)
BR (1) BR0210391A (enExample)
CA (1) CA2450167A1 (enExample)
WO (1) WO2002100399A1 (enExample)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039156A1 (es) * 2002-03-28 2005-02-09 Novartis Ag Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide
CA2485167A1 (en) * 2002-05-07 2003-11-20 The Government Of The United States Of America Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
DK1517915T3 (da) * 2002-06-11 2009-03-16 Lilly Co Eli Promedikamenter af excitatoriske aminosyrer
EP1535616B1 (en) * 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
CA2512111A1 (en) * 2003-01-07 2004-07-29 Merck And Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315571A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
DE10315572A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
WO2004113333A1 (ja) * 2003-06-23 2004-12-29 Dainippon Sumitomo Pharma Co., Ltd. 老人性痴呆症治療剤
WO2005007644A1 (ja) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
EP1697384B1 (en) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
HRP20040104A2 (en) * 2004-01-30 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
JP2007520526A (ja) * 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ コリン作動性受容体モジュレーターとしてのジアザビシクロアリール誘導体
US7674899B2 (en) * 2004-02-04 2010-03-09 Neurosearch A/S Dimeric azacyclic compounds and their use
WO2005080976A1 (ja) * 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007531755A (ja) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
JP2007531753A (ja) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1775283A4 (en) * 2004-07-14 2008-12-10 Japan Tobacco Inc 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
EP1777225A4 (en) * 2004-07-15 2009-06-24 Japan Tobacco Inc FUSED BENZAMIDE COMPOUND AND INHIBITOR OF VANILLOID RECEPTOR 1 (VR1) ACTIVITY
US7494986B2 (en) * 2004-07-20 2009-02-24 Bristol-Myers Squibb Company Cycloalkylamine derivatives as NK-1/SSRI antagonists
ATE396990T1 (de) 2004-07-28 2008-06-15 Schering Corp Makrocyclische inhibitoren der beta-sekretase
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
CA2576782A1 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1807082A4 (en) * 2004-10-26 2010-12-01 Janssen Pharmaceutica Nv INHIBITOR COMPOUNDS OF XA FACTORS
CA2587083A1 (en) * 2004-11-17 2006-05-26 Merck & Co., Inc. Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
JP5208510B2 (ja) * 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
ATE512147T1 (de) 2004-11-23 2011-06-15 Merck Sharp & Dohme Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
RS56194B1 (sr) * 2004-12-30 2017-11-30 Janssen Pharmaceutica Nv Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
BRPI0606636A2 (pt) * 2005-01-13 2009-07-07 Novartis Ag compostos macrocìclicos úteis como inibidores de bace
GB0504960D0 (en) * 2005-03-10 2005-04-20 Arakis Ltd Benzoxazocines
JP2008535863A (ja) 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
US8778919B2 (en) * 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007050612A1 (en) 2005-10-25 2007-05-03 Janssen Pharmaceutica N.V. 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace)
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
EP1963259B1 (en) * 2005-12-15 2012-02-15 AstraZeneca AB Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
DE102005062986A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
EP1987033B1 (en) * 2006-02-14 2010-08-25 NeuroSearch A/S Diazabicycloalkane derivatives and their medical use
US7759331B2 (en) * 2006-03-10 2010-07-20 Janssen Pharmaceutica Nv Pyridine-containing macroheterococylic compounds as kinase inhibitors
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
EP2001853A1 (en) * 2006-03-24 2008-12-17 NeuroSearch A/S Novel guanidine derivatives and their medical use
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
JP2009537598A (ja) * 2006-05-23 2009-10-29 ノイロサーチ アクティーゼルスカブ 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用
WO2007138039A1 (en) * 2006-05-30 2007-12-06 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use
WO2007137738A1 (de) * 2006-06-01 2007-12-06 Sanofi-Aventis Spiro-cyclische nitrile als protease-inhibitoren
EP2044084B1 (en) * 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki quinazoline derivatives
BRPI0715440A2 (pt) * 2006-07-20 2013-07-23 Novartis Ag compostos macrocÍclicos éteis como inibidores de bace
CA2656869A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Macrocyclic lactams
BRPI0808525A2 (pt) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
US20100063013A1 (en) * 2007-03-26 2010-03-11 Renata Oballa Cathepsin cysteine protease inhibitors
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2009024516A1 (en) * 2007-08-17 2009-02-26 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as nicotinic acetylcholine receptor ligands
WO2009024517A1 (en) * 2007-08-17 2009-02-26 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EA018582B1 (ru) * 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
EP2217602B1 (en) * 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
CA2713998A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
CN101970429B (zh) 2008-01-29 2013-05-29 詹森药业有限公司 可用作β-分泌酶(BACE)抑制剂的2-氨基喹啉衍生物
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
CA2757231A1 (en) * 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010128685A1 (en) * 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
WO2010145208A1 (en) * 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
PL2444395T3 (pl) * 2009-06-19 2016-06-30 D Western Therapeutics Inst Inc Podstawiona pochodna izochinoliny
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
CA2807687C (en) 2010-08-12 2019-01-08 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1, 5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
ES2380473B1 (es) * 2010-10-13 2013-02-19 Neuron Biopharma, S.A. Compuesto neuroprotector, hipocolesterolémico, antiinflamatorio y antiepiléptico.
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EA024647B1 (ru) * 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
JP5945592B2 (ja) 2011-06-17 2016-07-05 イーライ リリー アンド カンパニー Ｍｇｌｕ２受容体アゴニストとしてのビシクロ（３．１．０）ヘキサン−２，６−ジカルボン酸誘導体
JP6083818B2 (ja) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニスト
US20150141500A1 (en) * 2012-05-10 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological diseases
US20150141384A1 (en) * 2012-07-03 2015-05-21 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
FR2993563B1 (fr) * 2012-07-20 2015-12-18 Metabrain Res Derives de thiophenes utiles dans le traitement du diabete
PT2909204T (pt) 2012-10-12 2019-03-21 Dana Farber Cancer Inst Inc Inibidores de gsk3 e métodos de utilização dos mesmos
WO2014058071A1 (ja) 2012-10-12 2014-04-17 武田薬品工業株式会社 シクロプロパンアミン化合物およびその用途
WO2014075676A1 (en) * 2012-11-15 2014-05-22 V-Biotek Holding Aps Amines from trigonella foemum - graecum
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
GEAP201814248A (en) * 2014-02-19 2018-04-10 H Lundbeck As 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20161441A1 (es) 2014-04-11 2017-01-21 Takeda Pharmaceuticals Co Compuesto de ciclopropanamina y sus usos
SG10201808940WA (en) * 2014-05-09 2018-11-29 Suntory Holdings Ltd Nox inhibitor and nfкb inhibitor containing methoxyflavone
EP3157909B1 (en) * 2014-06-20 2021-04-07 Principia Biopharma Inc. Lmp7 inhibitors
BR112017005299A2 (pt) * 2014-09-17 2017-12-12 Ipsen Pharma Sas inibidores de lrrk2 cinase macrocíclicos
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JP6700293B2 (ja) * 2015-03-03 2020-05-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用
WO2016149248A1 (en) * 2015-03-15 2016-09-22 Emory University N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
AR105025A1 (es) * 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
JP2018531889A (ja) 2015-08-12 2018-11-01 ハー・ルンドベック・アクチエゼルスカベット Ｂａｃｅ１阻害剤としての２−アミノ−３−フルオロ−３−（フルオロメチル）−６−メチル−６−フェニル−３，４，５，６−テトラヒドロピリジン
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
CN109689673B (zh) * 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
WO2018027193A1 (en) * 2016-08-05 2018-02-08 The Regents Of The University Of California Gp130 modulators
JP7163280B2 (ja) * 2016-10-05 2022-10-31 エヌエスシー セラピューティクス ゲーエムベーハー ムスカリン性アセチルコリン受容体アゴニストの結晶性多形
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US20190388425A1 (en) * 2017-01-20 2019-12-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2018167176A1 (en) * 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
WO2018187630A1 (en) * 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
EP3625232B1 (en) * 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
GB201712567D0 (en) * 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4076659A1 (en) * 2019-12-19 2022-10-26 Latvian Institute Of Organic Synthesis Macrocyclic amides acting as plasmepsin inhbitors for the treatment of malaria

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM982594A0 (en) * 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors

Similar Documents

Publication Publication Date Title
JP2005505506A5 (enExample)
JP2012530703A5 (enExample)
JP2018518537A5 (enExample)
JP2004534064A5 (enExample)
JP2008509187A5 (enExample)
JP2005534614A5 (enExample)
CA2438991A1 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE60128258D1 (de) Indanylderivate zur Behandlung von Atemwegserkrankungen
JP2015510941A5 (enExample)
JP2006507220A5 (enExample)
JP2014525426A5 (enExample)
JP2005516967A5 (enExample)
JP2021501151A5 (enExample)
JP2019510082A5 (enExample)
JP2020503384A (ja) ポリエチレングリコールと局所麻酔薬とのコンジュゲートの非麻薬性鎮痛における使用
CN113260616B (zh) 用于治疗呼吸系统疾病的新型化合物
JPH0422889B2 (enExample)
WO2014129495A1 (ja) 眼疾患処置薬
JP2019502686A5 (enExample)
AU621041B2 (en) Beta-aminoethyl-substituted compounds and halo- azido- and phthalimido-ethyl-substituted phenyl intermediates
US20050065200A1 (en) Prostaglandin EP4 antagonist
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
JP2005514370A5 (enExample)
EP0785781B1 (en) Use of indole derivatives for the treatment of dermatological disorders peripheral neuropathied, arthritis, allergic or chronic obstructive airways disease, glaucoma and ocular inflammation
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途